Valuation: Alkermes plc

Market Cap 8.22B 7.14B 6.65B 6.11B 11.53B 785B 11.71B 78.39B 30.76B 391B 30.87B 30.19B 1,310B P/E 2026 *
-96.2x
P/E 2027 * 67.4x
Enterprise Value 8.96B 7.79B 7.25B 6.66B 12.57B 856B 12.77B 85.48B 33.55B 426B 33.66B 32.92B 1,428B EV / Sales 2026 *
4.91x
EV / Sales 2027 * 4.57x
Free-Float
89.44%
Yield 2026 *
-
Yield 2027 * -
1 day-2.08%
1 week-7.37%
1 month-5.28%
3 months+46.76%
6 months+44.56%
Current year+75.09%
1 week 47.66
Extreme 47.66
53.84
1 month 47.66
Extreme 47.66
55.67
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 01/02/1991
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
6/7/26 Sell

Compliance Officer

-2,034 0.0012%
1/7/26 Fiscal year

Chief Technology Officer

19,000 0.0114%
12/6/26 Sell

Director

-2,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-2.08%-7.37%+84.52%+71.65% 8.22B
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -1.56%+0.21%+64.64%+87.20% 25.86B
Weighted average by Cap. -1.61%+1.74%+79.94%+107.36%

Financials

2026 *2027 *
Net sales 1.82B 1.59B 1.48B 1.36B 2.56B 174B 2.6B 17.41B 6.83B 86.73B 6.85B 6.7B 291B 1.94B 1.69B 1.57B 1.44B 2.73B 186B 2.77B 18.55B 7.28B 92.42B 7.3B 7.14B 310B
Net income -89.92M -78.17M -72.76M -66.8M -126M -8.58B -128M -858M -337M -4.27B -338M -330M -14.33B 120M 105M 97.33M 89.36M 169M 11.48B 171M 1.15B 450M 5.72B 452M 442M 19.17B
Net Debt 744M 647M 602M 553M 1.04B 71.01B 1.06B 7.1B 2.78B 35.35B 2.79B 2.73B 119B 670M 582M 542M 498M 940M 63.95B 954M 6.39B 2.51B 31.84B 2.52B 2.46B 107B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
31/07/26 USD 48.99 -2.08% 1,624,487
30/07/26 USD 50.03 +3.50% 2,303,338
29/07/26 USD 48.34 -4.28% 4,149,635
28/07/26 USD 50.50 -4.23% 2,875,996
27/07/26 USD 52.73 -0.30% 1,402,922
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
48.99USD
Average target price
56.00USD
Spread / Average Target
+14.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock